

Registered Office :

Plot No. PF/21, Nr. Acme Pharma,
Opp. Teva Pharma, Sanand GICD - II,
Sanand, Ahmedabad – 382110, Gujarat (INDIA)

CIN.: L24230GJ2015PLC085451

Date: May 11, 2023

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai - 400051

Subject: Additional investment in Subsidiary Company by way of subscription towards Rights Issue-Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: Sotac Pharmaceuticals Limited (SYMBOL/ISIN: SOTAC/INE002D01012)

Dear Sir/Madam,

In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the our Company has made further investments to the extent of Rs. 5,10,00,000 in its Subsidiary Company, the **Sotac Lifesciences Private Limited (SLPL)** by way of Subscription to 51,00,000 (Fifty One Lacs Only) fully paid up equity shares of face value Rs.10/- each through Rights issue.

Today Subsidiary company allotted 51,00,000 equity shares of face value of Rs. 10/- each at cash for the total consideration of Rs. 5,10,00,000, to the Holding Company.

Subsequent to allotment of 51,00,000 Equity Shares by SLPL, holding of Sotac Pharmaceuticals Limited in SLPL has increased from 51.00 % to 51.26 % of equity share capital of Sotac Lifesciences Private Limited.

Further Details as required under regulation 30 of the listing regulations read with SEBI Circular No. CIR/CFO/CMD/4/2015 dated September 09, 2015 is attached herewith as an Annexure-A.

Kindly take the same on your records.

Thanking you.

For, Sotac Pharmaceuticals Limited

Sharadkumar Dashrathbhai Patel
Chairman and Managing Director
DIN: 07252252

Place: Ahmedabad

Registered Office :

Plot No. PF/21, Nr. Acme Pharma,
Opp. Teva Pharma, Sanand GICD - II,
Sanand, Ahmedabad – 382110, Gujarat (INDIA)

CIN.: L24230GJ2015PLC085451

Details under Regulation 30 of the Listing Regulations read with SEBI Circular No. CIR/ CFO/ CMD/ 4/ 2015 dated September 09, 2015:

Annexure-A

1.	Name of the target entity	Sotac Lifesciences Private Limited
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	<p>Yes. SLPL being a Subsidiary of the Company, the acquisition falls within related party transaction for which necessary approval has been taken.</p> <p>Except Mr. Sharadkumar Patel* (Promoter of Sotac Pharmaceuticals Limited), none of the Company’s promoter/ promoter group /group companies have any interest in Sotac Lifesciences Private Limited.</p> <p><i>* Post Allotment of 100,000 equity shares via Right issue, Mr. Sharadkumar Patel holds 1.02% in SLPL.</i></p> <p>The acquisition is via subscribing to the Rights Issue, pricing of which is based on a Valuation Report by Merchant Banker, i.e., Beeline Capital Advisors Private Limited dated April 09, 2023.</p>
3.	Industry to which the entity being acquired belongs	SLPL is engaged in the process to set up state of art manufacturing facility for various Pharmaceuticals formulations- allopathic, healthcare, neutraceuticals products.
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	<p>Further Investment in Subsidiary of our Company.</p> <p>As a result of this investment, the holding of Company in SLPL has increased from 51.00% to 51.26% of its Total Paid Up Capital.</p> <p>SLPL will utilize these funds for expansion of its production capacity for its existing products.</p>
5.	Brief details of any governmental or regulatory approvals required for the acquisition	None
6.	Indicative time period for completion of the acquisition	Equity Shares Allotted on May 11, 2023
7.	Nature of consideration - whether cash consideration or share swap and details of the same	Cash consideration
8.	Cost of acquisition or the price at which the shares are acquired	Acquisition of 5100000 equity shares of face value of Rs. 10/- per share aggregating to Rs. 5,10,00,000

SOTAC PHARMACEUTICALS LIMITED

(Formerly known as, Sotac Pharmaceuticals Private Limited)



Registered Office :

Plot No. PF/21, Nr. Acme Pharma,
Opp. Teva Pharma, Sanand GICD - II,
Sanand, Ahmedabad – 382110, Gujarat (INDIA)


CIN.: L24230GJ2015PLC085451

9.	Percentage of shareholding / control acquired and / or number of shares acquired	The holding of the Company in Sotac Lifesciences has increased from 51.00 % to 51.26 % of equity share capital of Sotac Lifesciences.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Line of business acquired- SLPL is engaged in the process to set up state of art manufacturing facility for various Pharmaceuticals formulations- allopathic, healthcare, nutraceuticals products. Date of Incorporation:- December 19, 2022 History of Last 3 years Turnover: Company commenced operations in FY 2023-24.

For, Sotac Pharmaceuticals Limited

Sharadkumar Dashrathbhai Patel
Chairman and Managing Director
DIN: 07252252

Place: Ahmedabad



Contact No.: 99135 62852, 87994 83159, 99250 45971



www.sotacpharma.com



sotacpharma@gmail.com